Short answer · Medically reviewed summary · Last updated: 2026-05-08
Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of rare, progressive neurological disorders with an estimated global prevalence of approximately 1 to 3 per million individuals. Because these disorders are frequently underdiagnosed or misdiagnosed as more common movement disorders, the true number of people living with Neurodegeneration with Brain Iron Accumulation is likely higher than current clinical registries suggest. Is Neurodegeneration with Brain Iron Accumulation considered rare? Yes, Neurodegeneration with Brain Iron Accumulation is classified as a rare disease.
What is the prevalence of Neurodegeneration with Brain Iron Accumulation?
Prevalence of Neurodegeneration with Brain Iron Accumulation: how many people are affected worldwide, differences by sex and region, with sources.
Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of rare, progressive neurological disorders with an estimated global prevalence of approximately 1 to 3 per million individuals. Because these disorders are frequently underdiagnosed or misdiagnosed as more common movement disorders, the true number of people living with Neurodegeneration with Brain Iron Accumulation is likely higher than current clinical registries suggest.
Is Neurodegeneration with Brain Iron Accumulation considered rare?
Yes, Neurodegeneration with Brain Iron Accumulation is classified as a rare disease. Due to the genetic heterogeneity of the condition—which includes subtypes like PKAN (Pantothenate Kinase-Associated Neurodegeneration) and PLAN (PLA2G6-Associated Neurodegeneration)—precise epidemiological data is difficult to consolidate. While some specific subtypes have a higher frequency in certain populations, the overall group remains ultra-rare worldwide.
Who is most affected by Neurodegeneration with Brain Iron Accumulation?
The age of onset for Neurodegeneration with Brain Iron Accumulation varies significantly by subtype, ranging from early childhood to adulthood. There is no significant gender bias, as most forms follow an autosomal recessive inheritance pattern, affecting males and females equally. While the disease is global, specific genetic mutations, such as those associated with PKAN, may show higher prevalence in specific ancestral groups due to founder effects.
What are the challenges in tracking prevalence data?
Accurate statistics for Neurodegeneration with Brain Iron Accumulation are hindered by several factors:
- Diagnostic delays: The complex, progressive nature of symptoms often leads to initial misdiagnosis with cerebral palsy or Parkinson's disease.
- Genetic complexity: There are at least 10 known genetic causes for NBIA, making uniform data collection across health systems difficult.
- Limited screening: Routine genetic testing for these specific iron-accumulation markers is not standard practice in many regions.
At DiseaseMaps.org, 9 people with Neurodegeneration with Brain Iron Accumulation have joined our community, providing a vital real-world perspective that complements clinical data by highlighting the lived experience of patients often missing from traditional epidemiological studies.
Next steps
- Consult a movement disorder specialist or a neurogeneticist to confirm a diagnosis through genetic testing.
- Connect with the 9 community members at DiseaseMaps.org to share experiences and coping strategies.
- Monitor clinical trial registries like ClinicalTrials.gov for research updates on iron-chelating therapies.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician regarding any medical condition.
References
- Orphanet: Rare Disease Database (Orpha.net)
- NIH Genetic and Rare Diseases Information Center (GARD)
- Online Mendelian Inheritance in Man (OMIM)
- NBIA Disorders Association
